September 2015- Volume 11, Issue 9

September 2015

In this Issue

Research & Development

Deerfield launches $550M healthcare VC fund

Deerfield launches $550M healthcare VC fund

Fund aims to advance transformative new therapies and enable improved models for the delivery of care

Paclical goes head-to-head with Abraxane

Paclical goes head-to-head with Abraxane

Oasmia Pharmaceutical announces positive top-line results for comparison study, showing nearly identical concentration curves for both

Just a gut feeling

Just a gut feeling

BGI study finds gut and oral microbiomes relevant to early diagnosis and treatment of rheumatoid arthritis

Immune regulation with PLX

Immune regulation with PLX

Recent study sheds light on mechanism of action for Pluristem’s placenta-based MSCs

Double-dealing in immunotherapy

Double-dealing in immunotherapy

AstraZeneca strikes pair of deals to strengthen its immunotherapy portfolio

Preclinical

DNA-based monoclonal antibody protects animals against dengue

DNA-based monoclonal antibody protects animals against dengue

Inovio Pharmaceuticals Inc. announced that its DNA-based monoclonal antibody (dMAb) targeting dengue virus provided protection against a lethal dengue virus challenge in mice

Preclinical progress for PLAP

Preclinical progress for PLAP

A recombinant molecule from CEVEC shows prolonged serum half-life in animal study

Summit publishes preclinical data on utrophin modulation in DMD

Summit publishes preclinical data on utrophin modulation in DMD

Data support utrophin modulation as mechanism to treat Duchenne muscular dystrophy regardless of mutation status

Moving away from animal models?

Moving away from animal models?

Group petitions FDA to change test procedures and give more weight to newer preclinical models

Scholar Rock beats drum for novel approach to disease

Scholar Rock beats drum for novel approach to disease

Innovative approach shows potential for therapeutic modulation of growth factor activation across TGFβ superfamily

Clinical Trials

Targeting TNF

Targeting TNF

Protalix’s anti-TNF fusion protein shows promising safety, biological activity in Phase 1

Looking to fill HIV vaccine void with VAC-3S

Looking to fill HIV vaccine void with VAC-3S

Clinical trial shows encouraging results for vaccine designed to prevent human immunodeficiency virus infection

Third-gen TKI for lung cancer

Third-gen TKI for lung cancer

Boehringer Ingelheim enters into an exclusive license agreement with Hanmi Pharmaceutical to develop third-generation EGFR-targeted therapy

It’s ‘T’ time

It’s ‘T’ time

Adaptimmune’s TCR-engineered T cells demonstrate ‘durable persistence, tolerability’ in clinical study of multiple myeloma patients

Contract Services

PAREXEL expands model-based discovery services

PAREXEL expands model-based discovery services

Expansion of QCD group fueled by absorption of GSK pharmacology

Consolidating CROs

Consolidating CROs

Chiltern to acquire Theorem Clinical Research and become eighth-largest CRO globally

BioClinica acquires MediciGroup

BioClinica acquires MediciGroup

Adds global patient recruitment-retention engine to accelerate clinical trials

Geneuity adopts Thermo’s next- gen tech and Oncomine assay

Geneuity adopts Thermo’s next- gen tech and Oncomine assay

Company is expanding early access to Thermo Fisher technology for upcoming services to pharma customer base

Discovery

Diabetes development team-up

Diabetes development team-up

Sanofi and Evotec join forces to develop next-generation therapies

How do T cells cross vessel walls to reach tumors?

How do T cells cross vessel walls to reach tumors?

Findings by Roswell Park highlight central role of CXCR3 receptor and suggest options for improving immunotherapies

Getting ahead with GPCRs

Getting ahead with GPCRs

MorphoSys-Heptares deal advances as Heptares exercises option

Bicoastal discoveries from Scripps

Bicoastal discoveries from Scripps

In Florida, an antibiotic/antitumor connection; in California, a bacterial enzyme that might fight nicotine addiction

Business & Government Policy

Oh say can you see, Watson?

Oh say can you see, Watson?

IBM’s $1B acquisition of Merge Healthcare could be good news for discovery and clinical trial communities

Emulating the lung

Emulating the lung

DefiniGEN licenses lung stem cell technology from University of Cambridge

Patent Docs: Federal Circuit construes patent litigation provisions of biosimilars law

Patent Docs: Federal Circuit construes patent litigation provisions of biosimilars law

One consequence of latest interpretation may be that it becomes more difficult for reference product sponsors to identify which of their patents a biosimilar applicant may be infringing

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Diagnostics

Say ‘ahhh’ for tumor screening?

Say ‘ahhh’ for tumor screening?

Saliva and plasma testing finds head and neck tumor DNA

A leg up on multiple sclerosis (and Alzheimer’s)

A leg up on multiple sclerosis (and Alzheimer’s)

Amarantus study shows MSPrecise helps diagnose multiple sclerosis patients with 84-percent accuracy

Marrying diagnosis and treatment

Marrying diagnosis and treatment

R-Biopharm and Apogenix team up to tackle glioblastoma multiforme

Editor's Focus

At your ‘service’

At your ‘service’

DDNews is rolling out a new section in the magazine (titled Contract Services) to cover news of the contract research and contract manufacturing sides of the pharma, biotech and diagnostics markets

Commentary

Out of order: When numbers fail

Out of order: When numbers fail

In our zeal to standardize healthcare and make medicine more scientific, we have to be careful not to ignore the natural variabilities of individuals within those populations

Guest Commentary: Building a problem or a solution?

Guest Commentary: Building a problem or a solution?

Removing the manufacturing facility as an obstacle to commercial success in cell therapy

Q&A

Q&A: On the front lines of biodefense and more with Soligenix

Q&A: On the front lines of biodefense and more with Soligenix

DDNews recently interviewed the Soligenix’s president and CEO, Dr. Christopher J. Schaber, to find out more about what they have done and what they plan in the areas of biodefense and vaccines in particular

Feature

Neuroscience 2015 Preview: Convening on the Lake Michigan shore

Neuroscience 2015 Preview: Convening on the Lake Michigan shore

Annual meeting of the Society for Neuroscience will tackle broad range of topics that includes traumatic brain injury, addiction, technology and aging
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022